Moderna (MRNA) excited analysts, though not as much investors, with its announcement this week that it planned to file for approval of its mRNA vaccine designed to protect older adults against respiratory syncytial virus (RSV) after it demonstrated success in a Phase III trial.
After…
Source: www.genengnews.com – Read more
The True Cost of Focusing on Cost Instead of Cost-Effectiveness
When payors consider only the cost of the medication and not the cost and risk to the patient, doctor, and healthcare system, the irony is
